Clinical Trials
Preoperative Intravesical Mitomycin-C Significantly Improves RFS and PFS in NMIBC
Lee et alInvestigative and clinical urology

In a single-center, open-label, randomized phase II trial evaluating patients with non-muscle-invasive bladder cancer (NMIBC), immediate preoperative intravesical chemotherapy (IPeIC) with mitomycin-C (MMC) significantly improved long-term oncological outcomes compared to transurethral resection of bladder tumor (TURBT) alone. Patients were randomized to receive either two split doses of IPeIC/MMC (40 mg/20 mL, n=33) or TURBT alone (n=38), with a median follow-up of 60.0 and 60.4 months, respectively.
IPeIC/MMC reduced the overall risk of recurrence by 76.8% (p=0.024), achieving a 3-year recurrence-free survival (RFS) rate of 90.7% versus 78.6% for TURBT alone. On multivariable analysis, IPeIC/MMC independently improved RFS (hazard ratio [HR] 0.266, p=0.044). Furthermore, preoperative MMC demonstrated superior progression-free survival (PFS), achieving 3-year and 5-year PFS rates of 100% compared to 92.1% and 85.8% in the control group (HR 0.078, p=0.014).
Exploratory RNA sequencing conducted on IPeIC-treated patients (3 with recurrence, 25 without) using a Monte Carlo-based resampling strategy identified low expression of Glutathione S-transferase Mu 1 (GSTM1) as the factor most strongly associated with tumor recurrence. The study concludes that preoperative MMC represents a safe and effective prophylactic alternative when standard immediate postoperative intravesical chemotherapy cannot be administered due to safety concerns or practical constraints, while highlighting GSTM1 as a potential target for biomarker-driven validation.
Key Takeaways
- Immediate preoperative intravesical mitomycin-C reduced bladder cancer recurrence risk by 76.8% and significantly improved 3-year recurrence-free survival compared to TURBT alone (90.7% vs. 78.6%; HR 0.266, p=0.044).
- Preoperative mitomycin-C demonstrated superior progression-free survival compared to control, achieving 3-year and 5-year PFS rates of 100% versus 92.1% and 85.8%, respectively (HR 0.078, p=0.014).
- Exploratory transcriptomic sequencing identified low Glutathione S-transferase Mu 1 (GSTM1) expression as the principal molecular factor associated with tumor recurrence following preoperative intravesical chemotherapy.
Read the original sourceInvestigative and clinical urology
